MAFK: A Potential Drug Target for Cancer and Other Diseases (G7975)

Target Name: MAFK

NCBI ID: G7975

MAFK

MAFK: A Potential Drug Target for Cancer and Other Diseases

MAFK (Nuclear factor erythroid-2, Ubiquitous (p18)) is a protein that plays a critical role in regulating various cellular processes in the body. It is a key transcription factor that is involved in the regulation of cell growth, differentiation, and apoptosis. MAFK has also been shown to be involved in the development and progression of various diseases, including cancer. As a result, MAFK has become a focus of interest for researchers and pharmaceutical companies as a potential drug target or biomarker.

MAFK is a nuclear transcription factor that is expressed in a variety of tissues and cells throughout the body. It is a key regulator of cell growth and differentiation, and is involved in the regulation of cell proliferation, cell survival, and cell death. MAFK plays a critical role in the development and maintenance of tissues and organs, and is involved in the regulation of processes such as cell adhesion, migration, and angiogenesis.

MAFK is also involved in the regulation of gene expression and has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that MAFK is involved in the regulation of the expression of genes that are involved in cell growth, differentiation, and apoptosis, and that its expression is often increased in tissues and cells that are susceptible to cancer.

In addition to its role in the regulation of cell growth and differentiation, MAFK is also involved in the regulation of cell death. It is a key regulator of apoptosis, which is the process by which cells undergo programmed cell death, and is involved in the regulation of the apoptosis-associated protein (AP-120). MAFK has been shown to play a role in the regulation of apoptosis and has been shown to protect against the deleterious effects of apoptosis in various tissues and cells.

MAFK is also involved in the regulation of inflammation, and has been shown to play a role in the development and progression of various inflammatory diseases, including cancer. For example, studies have shown that MAFK is involved in the regulation of the production of pro-inflammatory cytokines, and that its expression is often increased in tissues and cells that are susceptible to inflammation.

In addition to its role in the regulation of inflammation and cell death, MAFK is also involved in the regulation of cell signaling pathways. It is a key regulator of the TGF-β signaling pathway, which is involved in the regulation of cell growth and differentiation, and is involved in the development and progression of various diseases, including cancer.

Overall, MAFK is a protein that plays a critical role in regulating various cellular processes in the body, and is involved in the development and progression of various diseases. As a result, MAFK has become a focus of interest for researchers and pharmaceutical companies as a potential drug target or biomarker. Further research is needed to fully understand the role of MAFK in various tissues and cells, and to develop effective therapies based on its properties.

Protein Name: MAF BZIP Transcription Factor K

Functions: Since they lack a putative transactivation domain, the small Mafs behave as transcriptional repressors when they dimerize among themselves (PubMed:9150357). However, they act as transcriptional activators by dimerizing with other (usually larger) basic-zipper proteins, such as NFE2, NFE2L1/NRF1, NFE2L2/NRF2 and NFE2L3/NRF3, and recruiting them to specific DNA-binding sites (PubMed:9150357, PubMed:8932385). Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor (PubMed:9150357)

The "MAFK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAFK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets